Alto Neuroscience, a company focused on redefining psychiatry through personalized medicine, has closed a $100.0M Series B funding round. The capital infusion will advance its unique approach to developing highly effective treatments by leveraging individuals' neurobiology.
The company's Precision Psychiatry Platform™ stands out by measuring biomarkers such as EEG, wearable data, behavioral patterns, and genetics. This data, combined with AI-derived brain biomarkers, allows Alto to match patients with the specific drug they are most likely to respond to, aiming to help them get better faster.
